JP2004517087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517087A5 JP2004517087A5 JP2002547912A JP2002547912A JP2004517087A5 JP 2004517087 A5 JP2004517087 A5 JP 2004517087A5 JP 2002547912 A JP2002547912 A JP 2002547912A JP 2002547912 A JP2002547912 A JP 2002547912A JP 2004517087 A5 JP2004517087 A5 JP 2004517087A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclopentyl
- propionamide
- phenyl
- methanesulfonyl
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000004432 carbon atom Chemical group C* 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- -1 (4-methanesulfonyl-3-trifluoromethyl-phenyl) -N-quinolin-2-yl-propionamide Chemical compound 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003457 sulfones Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- QQZSSOYUTMZBTM-MRXNPFEDSA-N (2r)-n-(1,3-benzothiazol-2-yl)-2-(3-chloro-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 QQZSSOYUTMZBTM-MRXNPFEDSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- VXZQZJYMVXNSMK-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-(3-chloro-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 VXZQZJYMVXNSMK-UHFFFAOYSA-N 0.000 claims 2
- 238000005897 peptide coupling reaction Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940080818 propionamide Drugs 0.000 claims 2
- SOYSPEAIZRNEAT-LJQANCHMSA-N (2r)-2-(3-chloro-4-methylsulfonylphenyl)-3-cyclopentyl-n-quinolin-2-ylpropanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1N=C2C=CC=CC2=CC=1)CC1CCCC1 SOYSPEAIZRNEAT-LJQANCHMSA-N 0.000 claims 1
- OBWANNDHEQDAJQ-OAHLLOKOSA-N (2r)-n-(1,3-benzothiazol-2-yl)-3-cyclopentyl-2-(3,4-dichlorophenyl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@H](C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 OBWANNDHEQDAJQ-OAHLLOKOSA-N 0.000 claims 1
- KYRDLJWNZRNWSG-GOSISDBHSA-N (2r)-n-(1,3-benzothiazol-2-yl)-3-cyclopentyl-2-(4-methylsulfonylphenyl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 KYRDLJWNZRNWSG-GOSISDBHSA-N 0.000 claims 1
- AAQDRZIJUPVUDR-MRXNPFEDSA-N (2r)-n-(1,3-benzoxazol-2-yl)-2-(3-chloro-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1OC2=CC=CC=C2N=1)CC1CCCC1 AAQDRZIJUPVUDR-MRXNPFEDSA-N 0.000 claims 1
- ACXDSKDJMZEDQU-OAHLLOKOSA-N (2r)-n-(1,3-benzoxazol-2-yl)-3-cyclopentyl-2-(3,4-dichlorophenyl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@H](C(=O)NC=1OC2=CC=CC=C2N=1)CC1CCCC1 ACXDSKDJMZEDQU-OAHLLOKOSA-N 0.000 claims 1
- VXZQZJYMVXNSMK-MRXNPFEDSA-N (2r)-n-(1h-benzimidazol-2-yl)-2-(3-chloro-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 VXZQZJYMVXNSMK-MRXNPFEDSA-N 0.000 claims 1
- CLTWWLUHQCWZQM-OAHLLOKOSA-N (2r)-n-(1h-benzimidazol-2-yl)-3-cyclopentyl-2-(3,4-dichlorophenyl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@H](C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 CLTWWLUHQCWZQM-OAHLLOKOSA-N 0.000 claims 1
- IEDAZVJYMUBPHE-GOSISDBHSA-N (2r)-n-(1h-benzimidazol-2-yl)-3-cyclopentyl-2-(4-methylsulfonylphenyl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 IEDAZVJYMUBPHE-GOSISDBHSA-N 0.000 claims 1
- QZZFVLPXDBVTEZ-UHFFFAOYSA-N 2-(3-bromo-4-methylsulfonylphenyl)-3-cyclopentyl-n-quinolin-2-ylpropanamide Chemical compound C1=C(Br)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1N=C2C=CC=CC2=CC=1)CC1CCCC1 QZZFVLPXDBVTEZ-UHFFFAOYSA-N 0.000 claims 1
- SOYSPEAIZRNEAT-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-3-cyclopentyl-n-quinolin-2-ylpropanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1N=C2C=CC=CC2=CC=1)CC1CCCC1 SOYSPEAIZRNEAT-UHFFFAOYSA-N 0.000 claims 1
- AWINNBCBCPJDHB-UHFFFAOYSA-N 2-(3-cyano-4-methylsulfonylphenyl)-3-cyclopentyl-n-quinolin-2-ylpropanamide Chemical compound C1=C(C#N)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1N=C2C=CC=CC2=CC=1)CC1CCCC1 AWINNBCBCPJDHB-UHFFFAOYSA-N 0.000 claims 1
- DAFGCELMAUAKCZ-UHFFFAOYSA-N 3-cyclopentyl-2-(3,4-dichlorophenyl)-n-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=2CCCCC=2N=1)CC1CCCC1 DAFGCELMAUAKCZ-UHFFFAOYSA-N 0.000 claims 1
- HMOSAIJSNNENRZ-UHFFFAOYSA-N 3-cyclopentyl-2-(3,4-dichlorophenyl)-n-(6-fluoro-1,3-benzothiazol-2-yl)propanamide Chemical compound S1C2=CC(F)=CC=C2N=C1NC(=O)C(C=1C=C(Cl)C(Cl)=CC=1)CC1CCCC1 HMOSAIJSNNENRZ-UHFFFAOYSA-N 0.000 claims 1
- CCEZAKRHOWJHQJ-UHFFFAOYSA-N 3-cyclopentyl-2-(3,4-dichlorophenyl)-n-(6-methylsulfonyl-1,3-benzothiazol-2-yl)propanamide Chemical compound S1C2=CC(S(=O)(=O)C)=CC=C2N=C1NC(=O)C(C=1C=C(Cl)C(Cl)=CC=1)CC1CCCC1 CCEZAKRHOWJHQJ-UHFFFAOYSA-N 0.000 claims 1
- NPIXKNXGHOZWPG-UHFFFAOYSA-N 3-cyclopentyl-2-(3,4-dichlorophenyl)-n-quinolin-2-ylpropanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1N=C2C=CC=CC2=CC=1)CC1CCCC1 NPIXKNXGHOZWPG-UHFFFAOYSA-N 0.000 claims 1
- VDCMBEAIYGSKSX-UHFFFAOYSA-N 3-cyclopentyl-2-(4-methylsulfonyl-3-nitrophenyl)-n-quinolin-2-ylpropanamide Chemical compound C1=C([N+]([O-])=O)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1N=C2C=CC=CC2=CC=1)CC1CCCC1 VDCMBEAIYGSKSX-UHFFFAOYSA-N 0.000 claims 1
- RBFUJKPDVLOKBZ-UHFFFAOYSA-N 3-cyclopentyl-2-(4-methylsulfonylphenyl)-n-quinolin-2-ylpropanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1N=C2C=CC=CC2=CC=1)CC1CCCC1 RBFUJKPDVLOKBZ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- CDJWHCDZRBGAPD-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-2-(3-bromo-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(Br)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 CDJWHCDZRBGAPD-UHFFFAOYSA-N 0.000 claims 1
- QQZSSOYUTMZBTM-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-2-(3-chloro-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 QQZSSOYUTMZBTM-UHFFFAOYSA-N 0.000 claims 1
- CBSDSSJLVTWRIQ-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-2-(3-cyano-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(C#N)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 CBSDSSJLVTWRIQ-UHFFFAOYSA-N 0.000 claims 1
- OBWANNDHEQDAJQ-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-3-cyclopentyl-2-(3,4-dichlorophenyl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 OBWANNDHEQDAJQ-UHFFFAOYSA-N 0.000 claims 1
- SKOFSWUZPQBFAM-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-3-cyclopentyl-2-(4-methylsulfonyl-3-nitrophenyl)propanamide Chemical compound C1=C([N+]([O-])=O)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 SKOFSWUZPQBFAM-UHFFFAOYSA-N 0.000 claims 1
- KYRDLJWNZRNWSG-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-3-cyclopentyl-2-(4-methylsulfonylphenyl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 KYRDLJWNZRNWSG-UHFFFAOYSA-N 0.000 claims 1
- RNCVQIUDLLDVEL-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-3-cyclopentyl-2-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]propanamide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCCC1 RNCVQIUDLLDVEL-UHFFFAOYSA-N 0.000 claims 1
- XGRBXFPWATYYSK-UHFFFAOYSA-N n-(1,3-benzoxazol-2-yl)-2-(3-bromo-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(Br)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1OC2=CC=CC=C2N=1)CC1CCCC1 XGRBXFPWATYYSK-UHFFFAOYSA-N 0.000 claims 1
- AAQDRZIJUPVUDR-UHFFFAOYSA-N n-(1,3-benzoxazol-2-yl)-2-(3-chloro-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1OC2=CC=CC=C2N=1)CC1CCCC1 AAQDRZIJUPVUDR-UHFFFAOYSA-N 0.000 claims 1
- CXKICAVMPHVLQN-UHFFFAOYSA-N n-(1,3-benzoxazol-2-yl)-2-(3-cyano-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(C#N)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1OC2=CC=CC=C2N=1)CC1CCCC1 CXKICAVMPHVLQN-UHFFFAOYSA-N 0.000 claims 1
- ACXDSKDJMZEDQU-UHFFFAOYSA-N n-(1,3-benzoxazol-2-yl)-3-cyclopentyl-2-(3,4-dichlorophenyl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1OC2=CC=CC=C2N=1)CC1CCCC1 ACXDSKDJMZEDQU-UHFFFAOYSA-N 0.000 claims 1
- NDVQEFQAKFEDNT-UHFFFAOYSA-N n-(1,3-benzoxazol-2-yl)-3-cyclopentyl-2-(4-methylsulfonyl-3-nitrophenyl)propanamide Chemical compound C1=C([N+]([O-])=O)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1OC2=CC=CC=C2N=1)CC1CCCC1 NDVQEFQAKFEDNT-UHFFFAOYSA-N 0.000 claims 1
- DZCJSSWRHOHJCP-UHFFFAOYSA-N n-(1,3-benzoxazol-2-yl)-3-cyclopentyl-2-(4-methylsulfonylphenyl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1OC2=CC=CC=C2N=1)CC1CCCC1 DZCJSSWRHOHJCP-UHFFFAOYSA-N 0.000 claims 1
- MXRIOGBIGBFHTL-UHFFFAOYSA-N n-(1,3-benzoxazol-2-yl)-3-cyclopentyl-2-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]propanamide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1OC2=CC=CC=C2N=1)CC1CCCC1 MXRIOGBIGBFHTL-UHFFFAOYSA-N 0.000 claims 1
- WVGDMEFWIHUPTL-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-(3-bromo-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(Br)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 WVGDMEFWIHUPTL-UHFFFAOYSA-N 0.000 claims 1
- MXHYIYKLWIIIDN-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-(3-cyano-4-methylsulfonylphenyl)-3-cyclopentylpropanamide Chemical compound C1=C(C#N)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 MXHYIYKLWIIIDN-UHFFFAOYSA-N 0.000 claims 1
- CLTWWLUHQCWZQM-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-3-cyclopentyl-2-(3,4-dichlorophenyl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 CLTWWLUHQCWZQM-UHFFFAOYSA-N 0.000 claims 1
- QMQHSWHJSHWERL-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-3-cyclopentyl-2-(4-methylsulfonyl-3-nitrophenyl)propanamide Chemical compound C1=C([N+]([O-])=O)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 QMQHSWHJSHWERL-UHFFFAOYSA-N 0.000 claims 1
- IEDAZVJYMUBPHE-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-3-cyclopentyl-2-(4-methylsulfonylphenyl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 IEDAZVJYMUBPHE-UHFFFAOYSA-N 0.000 claims 1
- AYXGRWBIQWQTFT-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-3-cyclopentyl-2-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]propanamide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCCC1 AYXGRWBIQWQTFT-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25163700P | 2000-12-06 | 2000-12-06 | |
| PCT/EP2001/013870 WO2002046173A1 (en) | 2000-12-06 | 2001-11-28 | Fused heteroaromatic glucokinase activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004517087A JP2004517087A (ja) | 2004-06-10 |
| JP2004517087A5 true JP2004517087A5 (https=) | 2005-05-26 |
| JP4109111B2 JP4109111B2 (ja) | 2008-07-02 |
Family
ID=22952803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002547912A Expired - Fee Related JP4109111B2 (ja) | 2000-12-06 | 2001-11-28 | 縮合複素環式芳香族グルコキナーゼアクチベーター |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US6441184B1 (https=) |
| EP (1) | EP1341774B1 (https=) |
| JP (1) | JP4109111B2 (https=) |
| KR (1) | KR100545431B1 (https=) |
| CN (1) | CN1226294C (https=) |
| AR (1) | AR031627A1 (https=) |
| AT (1) | ATE316965T1 (https=) |
| AU (2) | AU2002221902B2 (https=) |
| BR (1) | BR0115999A (https=) |
| CA (1) | CA2429642C (https=) |
| DE (1) | DE60117059T2 (https=) |
| DK (1) | DK1341774T3 (https=) |
| ES (1) | ES2256340T3 (https=) |
| GT (1) | GT200100243A (https=) |
| MX (1) | MXPA03005119A (https=) |
| PA (1) | PA8534301A1 (https=) |
| PE (1) | PE20020753A1 (https=) |
| PT (1) | PT1341774E (https=) |
| UY (1) | UY27055A1 (https=) |
| WO (1) | WO2002046173A1 (https=) |
| ZA (1) | ZA200303748B (https=) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| RU2340605C2 (ru) | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Арилкарбонильные производные в качестве терапевтических средств |
| US6775812B2 (en) * | 2002-07-17 | 2004-08-10 | Hewlett-Packard Development Company, L.P. | Layout design process and system for providing bypass capacitance and compliant density in an integrated circuit |
| PL375149A1 (en) | 2002-10-03 | 2005-11-28 | F.Hoffmann-La Roche Ag | Indole-3-carboxamides as glucokinase (gk) activators |
| BR0314864A (pt) | 2002-10-03 | 2005-08-02 | Novartis Ag | Compostos orgânicos |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| US7262196B2 (en) * | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| RU2344132C2 (ru) * | 2003-06-20 | 2009-01-20 | Ф.Хоффманн-Ля Рош Аг | 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1 |
| BRPI0506662B8 (pt) | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| BRPI0507746A (pt) * | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto |
| KR20070007104A (ko) * | 2004-02-18 | 2007-01-12 | 아스트라제네카 아베 | 화합물 |
| BRPI0509573A (pt) * | 2004-04-02 | 2007-09-25 | Novartis Ag | derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 |
| US7781451B2 (en) * | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
| MXPA06012008A (es) * | 2004-04-21 | 2007-01-25 | Prosidion Ltd | Compuestos de amida tri(ciclo) sustituidos. |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| KR100890695B1 (ko) | 2004-08-12 | 2009-03-26 | 프로시디온 리미티드 | 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도 |
| GB0423044D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| KR20070085371A (ko) | 2004-10-16 | 2007-08-27 | 아스트라제네카 아베 | 페녹시 벤즈아미드 화합물의 제조 방법 |
| GB0423043D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| RU2398773C2 (ru) * | 2004-11-02 | 2010-09-10 | Баниу Фармасьютикал Ко., Лтд. | Арилоксизамещенное производное бензимидазола |
| DE102005012872A1 (de) * | 2005-03-19 | 2006-09-28 | Sanofi-Aventis Deutschland Gmbh | Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP1891069A1 (en) * | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| KR101346902B1 (ko) * | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
| JP2009500442A (ja) * | 2005-07-09 | 2009-01-08 | アストラゼネカ アクチボラグ | ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物 |
| EP2027113A1 (en) * | 2005-07-09 | 2009-02-25 | AstraZeneca AB | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| EP1905769B1 (en) | 2005-07-13 | 2017-03-29 | Msd K.K. | Heterocycle-substituted benzimidazole derivative |
| US9202182B2 (en) * | 2005-08-11 | 2015-12-01 | International Business Machines Corporation | Method and system for analyzing business architecture |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| WO2007051845A1 (en) * | 2005-11-03 | 2007-05-10 | Prosidion Ltd | Tricyclo substituted amides |
| EP1948614A2 (en) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
| AT503354B1 (de) * | 2006-02-22 | 2008-07-15 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von 3,4-disubstituierten phenylessigsäuren, sowie neue zwischenverbindungen |
| EP2001875A2 (en) | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| KR20090025358A (ko) | 2006-07-24 | 2009-03-10 | 에프. 호프만-라 로슈 아게 | 글루코키나제 활성화제로서의 피라졸 |
| TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| TW200825060A (en) * | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| KR20090090390A (ko) * | 2006-12-21 | 2009-08-25 | 아스트라제네카 아베 | Ｇｌｋ 활성제로서 유용한 신규 결정 화합물 |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| JP5248477B2 (ja) * | 2007-03-07 | 2013-07-31 | 杏林製薬株式会社 | グルコキナーゼ活性化物質 |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200934772A (en) * | 2008-01-15 | 2009-08-16 | Lilly Co Eli | Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
| JP5287730B2 (ja) * | 2008-01-18 | 2013-09-11 | アステラス製薬株式会社 | フェニルアセトアミド誘導体 |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| KR101608259B1 (ko) | 2008-04-28 | 2016-04-01 | 교린 세이야꾸 가부시키 가이샤 | 시클로펜틸아크릴산아미드 유도체 |
| EP2324028A2 (en) | 2008-08-04 | 2011-05-25 | AstraZeneca AB | Therapeutic agents 414 |
| JP5937353B2 (ja) * | 2008-08-19 | 2016-06-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | 冷感−メントール受容体拮抗剤 |
| AU2009290474A1 (en) | 2008-09-11 | 2010-03-18 | Pfizer Inc. | Heteroaryls amide derivatives and their use as glucokinase activators |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| EP2604604A1 (en) | 2009-03-11 | 2013-06-19 | Pfizer Inc | Benzofuranyl derivatives used as glucokinase inhibitors |
| WO2010116177A1 (en) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| AR076221A1 (es) * | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad |
| US8222416B2 (en) * | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
| CN102959076B (zh) | 2010-03-31 | 2015-09-16 | 斯克里普斯研究所 | 重编程细胞 |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| DK2681236T3 (en) | 2011-03-01 | 2018-04-16 | Synergy Pharmaceuticals Inc | PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS |
| ES2489297B1 (es) | 2013-01-22 | 2015-06-10 | Consejo Superior De Investigaciones Científicas (Csic) | Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
| SI3294713T1 (sl) | 2015-05-15 | 2021-08-31 | Aurigene Discovery Technologies Limited, | Nadomeščene spojine tetrahidrokinolinona kot ROR gama modulatorji |
| WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
| AR117122A1 (es) | 2018-11-20 | 2021-07-14 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CA3181722A1 (en) | 2020-06-08 | 2021-12-16 | Jing TENG | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3840550A (en) * | 1971-05-24 | 1974-10-08 | Ciba Geigy Corp | Certain 6-isothiocyanobenzothiazoles |
| US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| PL350669A1 (en) * | 1999-03-29 | 2003-01-27 | Hoffmann La Roche | Glucokinase activators |
-
2001
- 2001-11-28 DE DE60117059T patent/DE60117059T2/de not_active Expired - Lifetime
- 2001-11-28 PT PT01999565T patent/PT1341774E/pt unknown
- 2001-11-28 WO PCT/EP2001/013870 patent/WO2002046173A1/en not_active Ceased
- 2001-11-28 AT AT01999565T patent/ATE316965T1/de not_active IP Right Cessation
- 2001-11-28 JP JP2002547912A patent/JP4109111B2/ja not_active Expired - Fee Related
- 2001-11-28 EP EP01999565A patent/EP1341774B1/en not_active Expired - Lifetime
- 2001-11-28 DK DK01999565T patent/DK1341774T3/da active
- 2001-11-28 AU AU2002221902A patent/AU2002221902B2/en not_active Ceased
- 2001-11-28 BR BR0115999-2A patent/BR0115999A/pt not_active IP Right Cessation
- 2001-11-28 KR KR1020037007517A patent/KR100545431B1/ko not_active Expired - Fee Related
- 2001-11-28 CA CA002429642A patent/CA2429642C/en not_active Expired - Fee Related
- 2001-11-28 AU AU2190202A patent/AU2190202A/xx active Pending
- 2001-11-28 ES ES01999565T patent/ES2256340T3/es not_active Expired - Lifetime
- 2001-11-28 CN CNB018194494A patent/CN1226294C/zh not_active Expired - Fee Related
- 2001-12-04 US US10/006,168 patent/US6441184B1/en not_active Expired - Fee Related
- 2001-12-04 PE PE2001001217A patent/PE20020753A1/es not_active Application Discontinuation
- 2001-12-04 AR ARP010105639A patent/AR031627A1/es unknown
- 2001-12-04 US US10/007,091 patent/US6448399B1/en not_active Expired - Fee Related
- 2001-12-04 PA PA20018534301A patent/PA8534301A1/es unknown
- 2001-12-04 US US10/006,170 patent/US6545155B2/en not_active Expired - Fee Related
- 2001-12-05 UY UY27055A patent/UY27055A1/es not_active Application Discontinuation
- 2001-12-05 GT GT200100243A patent/GT200100243A/es unknown
-
2003
- 2003-05-14 ZA ZA200303748A patent/ZA200303748B/en unknown
- 2003-06-06 MX MXPA03005119A patent/MXPA03005119A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517087A5 (https=) | ||
| JP2020183410A5 (https=) | ||
| CA2660529A1 (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
| JP2005508349A5 (https=) | ||
| JP2007520440A5 (https=) | ||
| JP2004517049A5 (https=) | ||
| JP2004532209A5 (https=) | ||
| JP2005523922A5 (https=) | ||
| JP2006077019A5 (https=) | ||
| JP2010500345A5 (https=) | ||
| JP2004516314A5 (https=) | ||
| JP2004517080A5 (https=) | ||
| JP2010526146A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2014502979A5 (https=) | ||
| JPWO2023195529A5 (https=) | ||
| JP2022511477A5 (https=) | ||
| JP2005511697A5 (https=) | ||
| CA2710409A1 (en) | 6h-dibenz0 [b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists | |
| JP2005530811A5 (https=) | ||
| JP2006501201A5 (https=) | ||
| JP2010527985A5 (https=) | ||
| JP2010527984A5 (https=) | ||
| JP2012508251A5 (https=) | ||
| JP2004527492A5 (https=) |